- Scrip Originals
- Featured Topics
Brought to you by
Xynomic takes on abexinostat rights from undisclosed partner
15 Mar 2017
Xynomic Pharmaceuticals Inc. (oncology) licensed exclusive global rights from an undisclosed partner to develop, manufacture, and sell the HDAC inhibitor abexinostat.
- R&D and Marketing (Licensing)
Already a Biomedtracker subscriber? You have access to the full deal record through your subscription
Want to become a subscriber? Subscribers get more deal details, updates, deal financials and deal products.
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com